Weight-loss drugs don’t work for everyone. Here’s why.

Semaglutide has been hailed as a “game-changer” in the weight-loss industry, but not everyone who takes the drug will experience the advertised benefits. Writing for MedPage Today, Sophie Putka explains why some patients may have less favorable outcomes while on these drugs, how common these outcomes are, and more.

How Ozempic and Wegovy will impact the healthcare industry

The promise of new weight-loss drugs

In June 2021, FDA approved semaglutide as a treatment for chronic weight management in obese or overweight adults. The drug, which is made by Novo Nordisk, mimics a hormone called glucagon-like peptide-1 (GLP-1) to target areas...